- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Hetty E. Carraway, MD | Authors
Articles
ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AML
November 10, 2022
Video
Closing out their discussion, Drs Hetty Carraway and Eytan M. Stein highlight an ongoing clinical trial investigating a triplet therapy for AML.
ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML
November 10, 2022
Video
Dr Stein explains clinical trial data on the use of magrolimab plus azacitidine for patients with TP53-mutated AML.
Unmet Needs for Patients with Higher-Risk Myelodysplastic Syndrome
November 04, 2022
Video
Dr Carraway highlights some of the most urgent unmet needs for patients with higher-risk MDS.
Treating Patients with Myelodysplastic Syndrome and IDH or TP53 Mutations
November 04, 2022
Video
Eytan M. Stein, MD, discusses how to treat patients with MDS who have IDH or TP53 mutations, and whether there is a role for targeted therapy in this patient population.
Potential Shift in the Treatment Paradigm of Higher-Risk MDS with Magrolimab
October 27, 2022
Video
Dr Hetty Carraway muses on whether magrolimab plus azacitadine will be used as a standard treatment for higher-risk MDS in the future.
Magrolimab plus Azacitidine for Myelodysplastic Syndrome
October 27, 2022
Video
Drs Stein and Carraway explain the rationale for a magrolimab and azacitidine combination treatment for patients with higher-risk MDS with supporting data from 2 clinical trials.